Logic derived from Riccardi et al., Eur J Heart Fail 2024;26:411–431 (Figures 2–3, Table 2). For clinician use alongside bedside judgment and haemodynamic monitoring — not a substitute for either.
Vasopressor treatment stage
MECHANICAL EFFICIENCY
Mechanical efficiency
Mechanical inefficiency
Metabolic inefficiency
Patient profile
Select the closest match — recommendations update live.
Recommendation
AMI-CSHypotension prevailsMechanical efficiency
First-line
Rescue phase
If refractory / second-line
Escalation
Scope of evidence. Per the source review: no pharmacological therapy has proven mortality benefit in cardiogenic shock (DOREMI, LIDO, SURVIVE, SOAP-II and the Cochrane meta-analysis were consistently neutral or only hypothesis-generating). This tool encodes a therapeutic algorithm built from a mix of RCTs and observational registries where trial data is absent, and is intended to structure — not replace — bedside decision-making, invasive haemodynamic assessment, and escalation planning to MCS.